San Francisco AIDS Foundation

The San Francisco AIDS Foundation was founded in 1982 in San Francisco's Castro district as an emergency response to a quickly emerging health crisis. Its primary purpose was simply to assemble and disseminate critical information to gay men who were being diagnosed with a rare and frightening cancer.

As the health crisis grew to epidemic proportions and spread into new populations, the San Francisco AIDS Foundation correspondingly grew and responded to new challenges. Building upon its original mission to educate, the AIDS Foundation added comprehensive services for people living with HIV disease and AIDS and an aggressive public policy component to compel federal and state governments to address the growing epidemic.

Seventeen years later, the San Francisco AIDS Foundation is firmly established as a global leader in the fight against AIDS. With an annual budget of $18 million, over 100 employees, 450 volunteers and 120,000 individuals served this year, the AIDS Foundation continues to face daunting challenges at every turn with compassion, dignity and a sense of purpose.

SFAF Bulletin of Experimental Treatments for AIDS

Mailing Address:
1035 Market Street, Suite 400
San Francisco, CA 94103

Telephone Numbers:
Subscription Office: (800) 959-1059
Editorial/content: (415) 487-8060
Fax: (415) 487-8069


Other SFAF Sections

Categories Covered:Adverse Events, Comorbidities, and HIV, HIV Epidemiology, Etravirine (Intelence), Rilpivirine (Edurant), HIV Prevention Methods, Pregnancy, Childbirth, and HIV, Providing Quality HIV Care, HIV Treatments in Development, HIV Treatment Strategies, Managing Long-Term HIV Survivors, HIV and Mental Health Care, Maraviroc (Selzentry, Celsentri), Tipranavir (Aptivus), Zidovudine (AZT, Retrovir), Efavirenz (Sustiva, Stocrin), Nevirapine (Viramune), HIV Policy and Advocacy, Pediatric HIV Care, FDA-Approved HIV Medications, Managing HIV Drug Resistance, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate (Stribild), HIV Basic Science and Pathogenesis, HIV Education and Risk Management, PrEP (HIV Pre-Exposure Prophylaxis), First-Line HIV Treatment, U=U (Undetectable Equals Untransmittable, i.e. HIV Treatment as Prevention), HIV Case Management and Social Work, Meeting the Costs of HIV Care, Raltegravir (Isentress)

Latest by San Francisco AIDS Foundation

Sex Work, Criminalization and HIV: Lessons From Advocacy History

Table of Contents

Introduction What Do the Data Say? Scientifically Sound but Politically Unpalatable PEPFAR and Needle Exchange Gay Men: From "Vectors" to a Voice at the Table Criminalizing HIV Exposure and Transmission Sex Workers: The...

By Anna Forbes, M.S.S. for San Francisco AIDS Foundation

Cancer and HIV/AIDS

Evidence continues to accumulate showing that people with HIV and AIDS may develop cancer earlier and more often despite antiretroviral treatment, but study results are not entirely consistent. (For an overview, see "A Glass Half Full: Cancer Risk fo...

By Liz Highleyman for San Francisco AIDS Foundation

A Glass Half Full: Cancer Risk for People Living With HIV

Table of Contents

Introduction A Dividing Line: Before and After HAART Apples to Apples AIDS-Defining Cancers The New Frontier: Non-AIDS-Defining Cancers Hodgkin's Lymphoma Oncogenic Viruses The Role of Immune Health Prevention Nex...

By John-Manuel Andriote for San Francisco AIDS Foundation

Tenofovir/Emtricitabine PreP Shows Protective Effect

In late November, investigators released eagerly awaited data from the iPrEx trial showing that pre-exposure prophylaxis (PrEP) using tenofovir plus emtricitabine (the drugs in the Truvada combination pill) can help prevent HIV infection. A protectiv...

By Liz Highleyman for San Francisco AIDS Foundation

Drug Watch: Tesamorelin Update

Table of Contents

Introduction Fat and VAT Shrinking VAT With Growth Hormone Tesamorelin in the Pipeline Further Questions What's Next? Selected Sources


Since it first became available in the mid-1990s, highly active antir...

By Reilly O'Neal for San Francisco AIDS Foundation

Tesamorelin Approved for Lipodystrophy

In November, the FDA approved tesamorelin (Egrifta; formerly known as TH9507) for treatment of a type of lipodystrophy in HIV positive people taking antiretroviral therapy. Tesamorelin is a synthetic growth hormone-releasing factor that stimulates th...

By Liz Highleyman for San Francisco AIDS Foundation

California Budget Cuts & Consequences for People With HIV

Governor Brown calls his newly released budget proposal "a tough plan for tough times." In fact, it's worth noting that our new Governor is tasked with digging out of the largest financial deficit in the history of our state. That's no small task. We...

By Courtney Mulhern-Pearson for San Francisco AIDS Foundation

Development of Three Antiretroviral Drugs Halted

Given the effectiveness of current combination ART, it has become increasingly difficult for new drugs to demonstrate superiority to existing therapies in clinical trials.

In July, Merck announced that it was discontinuing development of its investi...

By Liz Highleyman for San Francisco AIDS Foundation

GSK572 Integrase Inhibitor Shines In Phase II

S/GSK1349572 -- or GSK572 for short -- is a second-generation integrase inhibitor being developed jointly by Shionogi and ViiV Healthcare. Prior research has shown that it works against HIV with some raltegravir-resistance mutations and has a high ge...

By Liz Highleyman for San Francisco AIDS Foundation

Raltegravir Safe During Pregnancy

Pregnant women with HIV can safely use raltegravir with no need for dose adjustment to account for changes in body size or blood volume, according to a study reported at ICAAC (abstract H-1668a).

Researchers looked at raltegravir pharmacokinetics in...

By Liz Highleyman for San Francisco AIDS Foundation